GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of …

– Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo –

– Today’s LGS data follows successful Phase 3 trial in Dravet syndrome announced in March 2016 –

– Company to hold investor conference call today at 8:00 a.m. EDT/13:00 BST –

LONDON, June 27, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added as an adjunct to the patient’s current treatment, achieved the primary endpoint of a significant reduction in the monthly

... read more at: https://globenewswire.com/news-release/2016/06/27/851481/0/en/GW-Pharmaceuticals-Announces-Positive-Phase-3-Pivotal-Trial-Results-for-Epidiolex-cannabidiol-in-the-Treatment-of-Lennox-Gastaut-Syndrome.html